Literature DB >> 24037915

Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis.

Xiaoyang Wen1, Hui Liu, Kailong Yu, Yang Liu.   

Abstract

A number of studies investigated the impact of matrix metalloproteinase 2 (MMP2) expression on the survival of patients with osteosarcoma, but no consistent results were reported. To derive a more precise estimate of the prognostic role of MMP2 expression in patients with osteosarcoma, we systematically reviewed the published studies and carried out a meta-analysis. Cohort studies assessing the prognostic role of MMP2 expression in patients with osteosarcoma were included. Pooled risk ratio (RR) with 95% confidence intervals (95%CI) was used to assess the prognostic role of MMP2 expression. Five cohort studies were eligible in the meta-analysis. Overall, high MMP2 expression was associated with increased risk of mortality in patients with osteosarcoma during the follow-up (fixed effects RR = 2.14, 95%CI 1.66-2.75, P < 0.001). Sensitivity analysis suggested that the pooled RR was stable and omitting a single study did not change the significance of the pooled RR. There was some possibility of publication bias risk in the meta-analysis. In conclusion, the meta-analysis suggests that osteosarcoma patients with high MMP2 expression have poorer prognosis compared with those with low MMP2 expression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24037915     DOI: 10.1007/s13277-013-1116-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  21 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.

Authors:  Mitsutoshi Uchibori; Yoshihiro Nishida; Tetsuro Nagasaka; Yoshihisa Yamada; Keisuke Nakanishi; Naoki Ishiguro
Journal:  Int J Oncol       Date:  2006-01       Impact factor: 5.650

Review 3.  Matrix metalloproteinase proteomics: substrates, targets, and therapy.

Authors:  Charlotte J Morrison; Georgina S Butler; David Rodríguez; Christopher M Overall
Journal:  Curr Opin Cell Biol       Date:  2009-07-16       Impact factor: 8.382

Review 4.  Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors.

Authors:  Sławomir Poletajew; Lukasz Fus; Aleksander Wasiutyński
Journal:  Ortop Traumatol Rehabil       Date:  2011 Nov-Dec

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer.

Authors:  Wei Dong; Hong Li; Yan Zhang; Heng Yang; Min Guo; Li Li; Tongjun Liu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2011-10-03       Impact factor: 3.848

Review 7.  Matrix metalloproteinases: regulators of the tumor microenvironment.

Authors:  Kai Kessenbrock; Vicki Plaks; Zena Werb
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

Review 8.  Surgical options for children with osteosarcoma.

Authors:  Robert J Grimer
Journal:  Lancet Oncol       Date:  2005-02       Impact factor: 41.316

9.  Matrix metalloproteinases: biologic activity and clinical implications.

Authors:  A R Nelson; B Fingleton; M L Rothenberg; L M Matrisian
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

Review 10.  Osteosarcoma.

Authors:  J Ritter; S S Bielack
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

View more
  15 in total

1.  Questions about XY Wen et al. entitled "Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis".

Authors:  Fanxiao Liu; Qingyu Zhang
Journal:  Tumour Biol       Date:  2015-02-08

2.  Molecular docking and inhibition of matrix metalloproteinase-2 by novel difluorinatedbenzylidene curcumin analog.

Authors:  Aamir Ahmad; Afreen Sayed; Kevin R Ginnebaugh; Vivek Sharma; Anita Suri; Arundhati Saraph; Subhash Padhye; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

3.  Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors.

Authors:  N Habel; M Vilalta; O Bawa; P Opolon; J Blanco; O Fromigué
Journal:  Oncogene       Date:  2014-07-28       Impact factor: 9.867

4.  Letter regarding Wen X.Y. et al. entitled "Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis".

Authors:  Hong-bin Guo; Tao Xiao
Journal:  Tumour Biol       Date:  2014-01-22

5.  Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis.

Authors:  Jian Chen; Meng-xiong Sun; Ying-qi Hua; Zheng-dong Cai
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-31       Impact factor: 4.553

6.  Establishment and analysis of osteosarcoma cell sublines with different metastatic characteristics.

Authors:  Zhi Li; Youjun Li; Nan Wang; Lifeng Yang; Wei Zhao; Xiandong Zeng
Journal:  Tumour Biol       Date:  2014-05-27

Review 7.  P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis.

Authors:  Jie Bu; Hui Li; Li-Hong Liu; Yu-Rong Ouyang; Hong-Bin Guo; Xiao-Yang Li; Tao Xiao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

8.  Expression of CXCR4 and MMP-2 is associated with poor prognosis in patients with osteosarcoma.

Authors:  Chen Gong; Kai Sun; Hui-Hua Xiong; Tal Sneh; Jing Zhang; Xiao Zhou; Peng Yan; Jian-Hua Wang
Journal:  Histol Histopathol       Date:  2020-04-21       Impact factor: 2.303

9.  TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.

Authors:  Xiu-Guo Han; Yan Li; Hui-Min Mo; Kang Li; Du Lin; Chang-Qing Zhao; Jie Zhao; Ting-Ting Tang
Journal:  Tumour Biol       Date:  2016-01-09

10.  Distribution and activity levels of matrix metalloproteinase 2 and 9 in canine and feline osteosarcoma.

Authors:  Christiane Gebhard; Andrea Fuchs-Baumgartinger; Ebrahim Razzazi-Fazeli; Ingrid Miller; Ingrid Walter
Journal:  Can J Vet Res       Date:  2016-01       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.